Drug Profile
Quisovalimab - Avalo Therapeutics
Alternative Names: AEVI-002; Anti-CD258 monoclonal antibody; Anti-LIGHT monoclonal antibody; Anti-TNFSF14-monoclonal-antibody; AVTX-002; CERC 002; MDGN-002; SAR 252067Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
- Developer Avalo Therapeutics; Kyowa Hakko Kirin; Sanofi; The Childrens Hospital of Philadelphia
- Class Anti-inflammatories; Antiasthmatics; Antivirals; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; COVID-19 pneumonia; Inflammatory bowel diseases; SARS-CoV-2 acute respiratory disease
- Phase I/II Crohn's disease
- Clinical Phase Unknown Ulcerative colitis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Crohn's-disease(Treatment-experienced, In adults) in USA (SC)
- 26 Jun 2023 Adverse events and efficacy data from a phase II PEAK trial in Asthma released by Avalo Therapeutics
- 11 May 2023 Avalo Therapeutics completes the phase-II PEAK trial in Asthma (In adults, In the elderly) in USA (SC) (NCT05288504)